Systemic Radiotherapy of Bone Metastases With Radionuclides

被引：17

作者：

Murray, I ^{[1
,2
]}

Du, Y. ^{[3
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Joint Dept Phys, Sutton SM2 5PT, Surrey, England

[2] Inst Canc Res, Sutton SM2 5PT, Surrey, England

[3] Royal Marsden NHS Fdn Trust, Nucl Med Dept, Sutton, Surrey, England

来源：

CLINICAL ONCOLOGY | 2021年 / 33卷 / 02期

关键词：

Bone metastases; PSMA; radium-223; samarium-153; strontium-89; RESISTANT PROSTATE-CANCER; ALPHA-PARTICLE EMITTERS; PHASE-II TRIAL; SM-153; LEXIDRONAM; ZOLEDRONIC ACID; SR-89; THERAPY; DOSE-RESPONSE; RADIUM-223; DICHLORIDE; SKELETAL METASTASES; TARGETED THERAPY;

D O I：

10.1016/j.clon.2020.11.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and samarium-153 ethylenediaminetetramethylene phophanate (EDTMP) for the palliation of pain from bone metastases, as well as the evidence for the use of radium-223 in metastatic castrate-resistant prostate cancer. Efforts to optimise treatments and improve response rates, either by safely increasing the radiation dose to bone metastases or by combining treatment with non-radiation-based therapies, are discussed. In addition, the development of both alpha- and beta-particle-emitting radiopharmaceuticals designed to target prostate-specific membrane antigen are reviewed. (C) 2020 The Royal College of Radiologists. Published by Elsevier Ltd. This

引用

页码：98 / 105

页数：8

共 73 条

[1] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy [J].

Ahmadzadehfar, Hojjat ;

Schlolaut, Stephan ;

Fimmers, Rolf ;

Yordanova, Anna ;

Hirzebruch, Stefan ;

Schlenkhoff, Carl ;

Gaertner, Florian C. ;

Awang, Zool Hilmi ;

Hauser, Stefan ;

Essler, Markus .

ONCOTARGET, 2017, 8 (61) :103108-103116

[2] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 [J].

Ahmadzadehfar, Hojjat ;

Wegen, Simone ;

Yordanova, Anna ;

Fimmers, Rolf ;

Kuerpig, Stefan ;

Eppard, Elisabeth ;

Wei, Xiao ;

Schlenkhoff, Carl ;

Hauser, Stefan ;

Essler, Markus .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) :1448-1454

[3] Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone [J].

Alberts, AS ;

Smit, BJ ;

Louw, WKA ;

vanRensburg, AJ ;

vanBeek, A ;

Kritzinger, V ;

Nel, JS .

RADIOTHERAPY AND ONCOLOGY, 1997, 43 (02) :175-179

[4] High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases [J].

Anderson, PM ;

Wiseman, GA ;

Dispenzieri, A ;

Arndt, CAS ;

Hartmann, LC ;

Smithson, WA ;

Mullan, BP ;

Bruland, OS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :189-196

[5]

Baba K, 2018, HELL J NUCL MED, V21, P15, DOI 10.1967/s002449910702

[6] Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial [J].

Basch, Ethan ;

Autio, Karen ;

Ryan, Charles J. ;

Mulders, Peter ;

Shore, Neal ;

Kheoh, Thian ;

Fizazi, Karim ;

Logothetis, Christopher J. ;

Rathkopf, Dana ;

Smith, Matthew R. ;

Mainwaring, Paul N. ;

Hao, Yanni ;

Griffin, Thomas ;

Li, Susan ;

Meyers, Michael L. ;

Molina, Arturo ;

Cleeland, Charles .

LANCET ONCOLOGY, 2013, 14 (12) :1193-1199

[7]

BAYOUTH JE, 1994, J NUCL MED, V35, P63

[8] A DIRECT MEASUREMENT OF SR-89 ACTIVITY IN BONE METASTASES [J].

BENJOSEF, E ;

MAUGHAN, RL ;

VASAN, S ;

PORTER, AT .

NUCLEAR MEDICINE COMMUNICATIONS, 1995, 16 (06) :452-456

[9] Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases [J].

Blacksburg, Seth R. ;

Witten, Matthew R. ;

Haas, Jonathan A. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (03)

[10]

BUCHALI K, 1988, EUR J NUCL MED, V14, P349

← 1 2 3 4 5 6 7 8 →